Informasjon

Forstørret hjerte - hypertrofisk kardiomyopati

Prognose

Mange pasienter kan være uten symptomer hele livet og ha normal livslengde. Hos de som får symptomer, utvikler disse seg vanligvis langsomt. Over tid kan det oppstå hjertesvikt eller angina pectoris. Plutselig død kan forekomme, men moderne behandling med hjertestarter og hjertekirurgi har som formål å minske risikoen for slike hendelser.

Dette dokumentet er basert på det profesjonelle dokumentet "Kardiomyopati, hypertrofisk". Referanselisten for dette dokumentet vises nedenfor.

Elliot PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2733-79. pmid:25173338 PubMed
Spirito P, Autore C. Management of hypertrophic cardiomyopathy. BMJ 2006; 332: 1251-5. British Medical Journal
Maron BJ, Olivotto I, Maron MS. The dilemma of left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy: do patients with gradients really deserve prophylactic defibrillators? Eur Heart J. 2006 Aug;27(16):1895-7. PMID: 16818455 PubMed
Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015; 65:1249-54. PMID: 25814232 PubMed
Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol. 2008;19:104-110. PMID: 17916152 PubMed
Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004; 363: 1881-91. PubMed
Maron BJ, Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 1998; 81: 1339-44. PubMed
Maron BJ, Niimura H, Casey SA, et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol 2001; 38: 315-21. PubMed
Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003; 349: 1027-35. New England Journal of Medicine
Wu G, Liu J, Wang S, et al. N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy. Heart 2021. pmid:33361398 PubMed
Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA 2002; 287: 1308-20. Journal of the American Medical Association
Chen AS, Bent RE, Wheeler M, et al. Large Q and S waves in lead III on the electrocardiogram distinguish patients with hypertrophic cardiomyopathy from athletes. Heart 2018. doi:10.1136/heartjnl-2017-312647 DOI
Gandjbakhch E, Gackowsi A, Tezenas du Montcel, et al. Early identification of mutation carriers in familial hypertrophic cardiomyopathy by combined echocardiography and tissue Doppler imaging. Eur Haert J 2010;31:1599-607. PubMed
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020. pmid:33215938 PubMed
Maron BJ.The 2009 International Hypertrophic Cardiomyopathy Summit . Am J Cardiol 2010; 105: 1164-8. PubMed
Moon JCC, McKenna WJ, McCrohon JA et al. Towards clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41: 1561-67. PubMed
Carsten R, Norbert MW, Michael JH, Susan AC, Prasad P, Neeta P, et al. Utility of Cardiac Magnetic Resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005; 112: 855-61. Circulation
Leonardo S, Rainieri C, De Ferrari GM, et al. Usefulness of cardiac magnetic resonance in assessing the risk of ventericual arrhythmias and of sudden death in patients with hypertrophic cardiomyopathy. Eur Heart J 2009; 30: 2003-10. European Heart Journal
Sen-Chowdry S, McKenna WJ. Non-invasive risk-stratification in hypertrophic cardiomyopathy: don`t throw out the baby with the bathwater. Eur Heart J 2008; 29: 1600-02.
O'Mahony C, Tome-Esteban M, Lambiase PD, et al. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart. 2013;99:534-541. PubMed
Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary. Circulation 2011; 124: 2761-96. Circulation
Michels M, Soliman OI,Ten Cate FJ, et al. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. Eur Heart J 2009; 30: 2953-8. European Heart Journal
Christiaans I, Birnie E, Bonsel GJ, et al. Manifest disease, risk factors for sudden death, and large cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. Eur Heart J 2011; 32: 1161-70. European Heart Journal
Corrado D, Pelliccia A, Bjørnstad H, Vanhees L. Preparticipation screening of young competitive athletes for prevention of sudden death: proposal of a common European protocol. Eur Heart J 2005; 26: 516-24. European Heart Journal
Corrado D, Basso C, Pavei A, et al. Trends in sudden cardiovascular death in young competetive athletes after implementation of a preparticipation screening program. JAMA 2006; 296: 1593-601. Journal of the American Medical Association
Bille K, Figueiras D, Schamasch P, et al. Sudden cardiac death in athletes: the Lausanne recommendations. Eur J Cardiovasc Prev Rehabil 2006; 13: 859-75. PubMed
Mukherjee M, Abraham T. Hypertrophic cardiomyopathy. BMJ Best Practice, last updated Sep 17, 2014.
Gati S, Sharma S. Exercise prescription in individuals with hypertrophic cardiomyopathy: what clinicians need to know. Heart 2022. pmid:35197306 PubMed
Sweeting J, Ingles J, Timperio A, et al. Physical activity in hypertrophic cardiomyopathy: prevalence of inavtivity and preceived barriers. Open Heart 2016. doi:10.1136/openhrt-2016-000484 DOI
Lampert R, Ackerman MJ, Marino BS, et al. Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol 2023. pmid:37195701 PubMed
Dybro AM, Rasmussen TB, Nielsen RR, et al. Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2021; 78: 2505-17. pmid:34915981 PubMed
Spertus JA, Fine JT, Elliott P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 2021;397:2467-75. PMID: 34004177 PubMed
Nishimura RA, Holmes DR Jr. Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004; 350: 1320-7. New England Journal of Medicine
Thaman R, Varnava A, Hamid MS, et al. Pregnancy related complications in women with hypertrophic cardiomyopathy. Heart 2003; 89: 752-56. PubMed
Autore C, Conte MR, Piccininno M, Bernabò P, Bonfiglio G, Bruzzi P, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 40: 1864-9. PubMed
Cui H, Schaff HV, Wang S, et al. Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2022; 79: 1647-55. pmid:35483751 PubMed
Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH 3rd. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol 2000; 36: 852-55. PubMed
LIebregts M, Faber L, Jensen MK, et al. Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy. JACC Cardiovasc Interv. 2017; 10: 1134-43. pmid:28595881 PubMed
Batzner A, Pfeiffer B, Neugebauer A, et al. Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy. J Am Coll Cardiol 2018; 72: 3087-94. pmid:30545446 PubMed
Maron BJ, Yacoub M, Dearani JA. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back to European patients. Eur Heart J 2011; 32:1055-8. European Heart Journal
Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003; 24: 1965-91. European Heart Journal
Pelliccia A, Corrado D, Bjornstad HH, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26: 1422-45. European Heart Journal
Elliott PM, Gimeno Blanes JR, Mahon NG, McKenna WJ. Relation between the severity of left ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001; 357: 420-24. PubMed
Maron BJ, Semsarian C. Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy. Eur Heart J 2010; 31: 1551-3. European Heart Journal
Maron BJ, Chaitman BR, Ackerman MJ, Bayés de Luna A, Corrado D, Crosson JE, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109: 2807-16. Circulation
Pelliccia A, Corrado D, Bjørnstad HH, et al. Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis. Eur J Cardiovasc Prev Rehabil 2006; 13: 876-85. PubMed
Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348: 295-303. New England Journal of Medicine
Autore C, Bernabò P, Barillà CS, Bruzzi P, Spirito P. The prognosis importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol 2005; 45: 1076-80. PubMed

Er du helsepersonell?

Ved å oppgi dette kan du få bedre tilpasset innhold om du har formell helsefaglig kompetanse

Mest lest i dag

Psykisk helse

Metakognitiv terapi - mindre overtenking

Metakognitiv terapi hjelper pasienter med angst og depresjon til å redusere overtenking og symptomplager. I MCT lærer du å vurdere hvordan du vil forholde deg til negative tanker og følelser, sier professor Hans M. Nordahl ved NTNU.

Kun for helsepersonell

Hydrokortison ved samfunnservervet lungebetennelse

Alvorlig samfunnservervet lungebetennelse er ingen uvanlig sykdom og har høy dødelighet. Hva vet vi om effekten av tilleggsbehandling med glukokortikoid?

Familie

Når skal barnet legge seg?

Her er en pekepinn på hva barn i ulike aldre trenger av søvn i døgnet. Og når de bør legge seg for for natta.

Forstørret hjerte - hypertrofisk kardiomyopati

Hopp til innhold

Prognose

Er du helsepersonell?

Mest lest i dag

Metakognitiv terapi - mindre overtenking

Hydrokortison ved samfunnservervet lungebetennelse

Når skal barnet legge seg?

Informasjon

Hold deg oppdatert

Forstørret hjerte - hypertrofisk kardiomyopati

Hopp til innhold

Prognose

Er du helsepersonell?

Andre leste også dette

Hjertemuskelbetennelse (myokarditt)

Kronisk hjertesvikt

Digitalisforgiftning

Mest lest i dag

Metakognitiv terapi - mindre overtenking

Hydrokortison ved samfunnservervet lungebetennelse

Når skal barnet legge seg?